Targets › GUCY1A2
11 programs from 11 companies in 23 trials: 9 Phase 2, 6 Phase 4, 5 Phase 3, 3 Phase 1; Cardiovascular, Oncology, Genitourinary; next expected readout Jun 2027.
Alpha subunit of soluble guanylate cyclase (sGC), a central enzyme in nitric oxide (NO) signaling. Functions as the main intracellular receptor for NO. Upon NO binding, catalyzes the conversion of GTP to cyclic GMP (cGMP) and thereby transducing NO signal into a ubiquitous intracellular second messenger..; FUNCTION: [Isoform 2]: Acts as a negative regulator of guanylyl cyclase activity as it forms non-functional…. (UniProt, P33402)
Open in Phaseline: the race on GUCY1A2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cheng-Kung University Hospital | Nitroglycerin Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 4 | Pancreatitis | Jul 2027 |
| Children's Hospital Medical Center, Cincinnati | Nitric Oxide Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 3 | AKI | Jun 2027 |
| Xijing Hospital | Nitric Oxide Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 3 | Nitric Oxide | Mar 2028 |
| Bayer | Riociguat Soluble guanylate cyclase positive allosteric modulator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 3 | Hypertension, Pulmonary; Chronic Thromboembolic Pulmonary Hypertension; Pulmonary Arterial Hypertension | May 2028 |
| Akebia Therapeutics | Praliciguat Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 2 | Focal Segmental Glomerulosclerosis | Jun 2027 |
| Kardigan | Ataciguat Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 2 | Moderate Aortic Valve Stenosis | Aug 2028 |
| Merck & Co. (MSD) | Vericiguat Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 2 | Heart Failure; Heart Failure With Reduced Ejection Fraction (HFrEF); Endothelial Dysfunction; Post-COVID ME/CFS … | Aug 2029 |
| Steven Messe | Nitric Oxide Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 2 | Stroke | – |
| Beni-Suef University | Nitroglycerin Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 2 | COPD | – |
| Mayo Clinic | Isosorbide Mononitrate Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 1 | Malignant Digestive System Neoplasm | Apr 2028 |
| Vanderbilt University | Nitroglycerin Soluble guanylate cyclase activator | GUCY1B1, GUCY1A2, GUCY1A1 | Phase 1 | Hypertension | Jul 2028 |
Heart Failure (3) Chronic Thromboembolic Pulmonary Hypertension (2) Pulmonary Arterial Hypertension (2) Nitric Oxide (1) COPD (1) Heart Failure With Reduced Ejection Fraction (HFrEF) (1) Endothelial Dysfunction (1) Post-COVID ME/CFS (1) Breast Cancer (1) Calcific Aortic Valve Disease (1) Decompensated Heart Failure (1) Pancreatitis (1)
small molecule (11)
Xijing Hospital (1) Beni-Suef University (1) Merck & Co. (MSD) (1) National Cheng-Kung University Hospital (1) Children's Hospital Medical Center, Cincinnati (1) Kardigan (1) Bayer (1) Akebia Therapeutics (1) Vanderbilt University (1) Mayo Clinic (1) Steven Messe (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.